

**bioMérieux's multi-year tender award with UK's NHSBT  
includes ITL's SampLok® Sampling Kit**

ITL BioMedical, a division of ITL (ASX: ITD) that sets industry standards for the innovative design and production of biological sampling systems for human and animal use, is pleased to announce that bioMérieux, its business partner and distributor of several ITL products, has been awarded a multi-year agreement with UK National Health Service Blood and Transplant (NHSBT) for bacterial screening of platelets in the UK. This agreement includes ITL BioMedical's highly innovative SampLok® Sampling System ("SSK").

ITL BioMedical has partnered with bioMérieux for more than five years for the supply of SSK in the United Kingdom, generating \$11.5M in revenue. bioMérieux selected SSK as the preferred sampling transfer device in response to this tender based upon its established global acceptance and use.



Following an extensive tender process bacT/ALERT® bioMérieux's automated microbial detection system was selected by the NHSBT among a number of technologies for bacterial risk reduction in platelet components. SSK is the sampling device used to transfer platelets from the platelet bag to bioMérieux's reagent bottle.

SSK is a state of the art medical device providing safety and process efficiency for use in the global blood banking market to transfer platelet samples when performing bacterial detection testing.

The agreement builds upon SSK's recent selection and implementation by OneBlood, a large U.S. blood bank, a contract extension with a second large U.S. blood bank, the grant of the SSK patent in the U.S. as well as Taiwan FDA approval for the product.

"This NHSBT award for bioMérieux's standard setting bacterial detection testing technology is very exciting and ITL is pleased to have SampLok Sampling Kit included," commented Bill Mobbs, Executive Chairman of ITL BioMedical. "This tender award is in line with ITL's goal to continue SSK sales growth on a global level."

Bill Mobbs  
Executive Chairman

**ITL Limited ABN 16 088 212 088**  
**Unit 1, 63 Wells Road**  
**Chelsea Heights, Victoria, 3196**

ITL is an innovative diversified medical technology company that creates and manufactures leading edge medical devices for Operating Theatres, Bloodbanks and laboratories.

ITL's patented medical devices are sold in over 50 countries and protect healthcare workers in millions of procedures annually.

ITL's wholly owned subsidiary MyHealthTest creates and markets highly innovative direct to consumer pathology testing for major chronic diseases.



Ranked 16<sup>th</sup> most Innovative Company by the AFR  
Innovative Companies Awards

**Australian Securities Exchange**  
Code: ITD

**Ordinary Shares**  
95,928,314

**Board of Directors**

Bill Mobbs	Executive Chairman
Mark Peatey	Non-executive Director
Andrew Turnbull	Non-executive Director
Trevor Doolan	Chief Financial Officer & Company Secretary

**ITL Contact**  
Trevor Doolan      Company Secretary  
Phone:              +61 3 8773 3050  
Email:                [info@itl-limited.com](mailto:info@itl-limited.com)

[www.itl-limited.com](http://www.itl-limited.com)

**Media**  
Ben Knowles      Walbrook IR  
Phone:              +61 426 277 760  
Email:                [ben.knowles@walbrookir.com.au](mailto:ben.knowles@walbrookir.com.au)

**About ITL BioMedical**

ITL BioMedical is a division of ITL that sets industry standards for the innovative design and production of biological sampling systems for human and animal use. The Division's patented medical devices focus on safety and process efficiency for end-users and their blood donors and patients in healthcare markets worldwide. For more information visit [ITLBioMedical.com](http://ITLBioMedical.com).

**About bioMérieux**

*Pioneering Diagnostics*

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms and preventing contamination in blood components, agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on the Euronext Paris stock market

(Symbol: BIM/Reuters: BIOX.PA/Bloomberg: BIM.FP – ISIN: FR0010096479)

Corporate website: [www.biomerieux.com](http://www.biomerieux.com)

Industry website: [www.biomerieux-industry.com](http://www.biomerieux-industry.com)